Cardiovascular Today—June 25, 2026

This week’s Cardiovascular update highlights regulatory activity, clinical advances, device innovation, workflow improvements, and emerging evidence shaping cardiovascular care.

In Today’s Newsletter

Dive deeper

🫀 ViMech valve-in-valve approach for failed mechanical aortic valves [1] [EU • 19 Jun 2026]

https://cardiovascularnews.com/vimech-procedure-offers-new-hope-for-treating-patients-with-mechanical-aortic-valve-failure/
Context: Ignacio Amat-Santos (Hospital Clínico Universitario de Valladolid) described ViMech for dysfunctional mechanical aortic valves.
Key point: The approach fractures mechanical valve discs, captures fragments in an embolic filter, then deploys a TAVI valve.
Implication: May influence valve strategy and reintervention planning pending broader clinical data.

📱 Mount Sinai STEMIcathAID coordinates STEMI care [2] [US • 24 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/acute-coronary-syndromes/new-digital-platform-gets-clinicians-same-page-when-treating-heart-attacks
Context: Mount Sinai Health System first deployed STEMIcathAID in 2021 for STEMI transfers and cath lab activation.
Key point: The platform shares ECGs, alerts clinicians, and has been used in nearly 600 STEMI cases.
Implication: Could streamline initiation and adherence via remote prescribing and logistics.

🩺 Sex-specific TAVR vs SAVR outcomes in meta-analysis [3] [23 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/structural-heart-disease/tavr/sex-specific-outcomes-after-tavr-and-savr-key-takeaways-new-meta-analysis
Context: JACC: Advances meta-analysis included nine randomized trials and more than 9,500 severe aortic stenosis patients.
Key point: TAVR showed early benefit in women, mainly intermediate- and high-risk patients, but not at five years.
Implication: May influence prescriber choice and payer reviews pending full data.

🤖 GuideAI Health VAOT receives FDA clearance [4] [US • 23 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/vascular-endovascular/fda-clears-ai-software-flagging-signs-vascular-disease
Context: GuideAI Health is a Boston-based medtech company founded by radiologists.
Key point: FDA cleared VascularAssist Occlusion Triage to flag suspected vascular occlusion in lower-extremity imaging.
Implication: Access programs may expand screening, initiation, and follow-up at scale.

🔬 VahatiCor enrolls first US patient in SERRA-I CMD study [5] [US • 19 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/vascular-endovascular/fda-clears-ai-software-flagging-signs-vascular-disease
Context: VahatiCor enrolled the first US patient at Yale-New Haven Hospital in the SERRA-I early feasibility study.
Key point: A-Flux Reducer System is being evaluated for symptomatic coronary microvascular dysfunction.
Implication: May influence prescriber choice and payer reviews pending full data.

🌊 Cardiawave Valvosoft enters routine European use [6] [EU • 18 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/vascular-endovascular/fda-clears-ai-software-flagging-signs-vascular-disease
Context: Cardiawave’s Valvosoft received CE mark clearance in late 2025 and uses noninvasive high-intensity ultrasound.
Key point: The system entered first routine European clinical use for severe symptomatic aortic stenosis patients not suited to valve replacement.
Implication: May expand screening, initiation, and follow-up at scale.

⚠️ FDA early alert on Impella introducer leakage risk [7] [US • 19 Jun 2026]

https://cardiovascularbusiness.com/topics/clinical/interventional-cardiology/blood-may-leak-out-impella-introducers-due-manufacturing-defect
Context: FDA issued an early alert for Johnson & Johnson MedTech Impella introducer sheaths.
Key point: Leakage may occur from 14 French and 23 French introducers, with major bleeding reports noted by the company.
Implication: Introduces safety monitoring that may affect procedure planning and inventory use.

🎛️ Vibration-based EP lead extraction reaches first-in-human study [8] [Israel/Poland • 18 Jun 2026]

https://cardiovascularbusiness.com/topics/cardiac-imaging/ep-lab/vibrations-used-extract-ep-leads-first-human-study
Context: JACC: Clinical Electrophysiology published a prospective first-in-human study across centers in Jerusalem and Rzeszów.
Key point: The vibration-based method achieved complete extraction in 10 patients with 18 leads and no device-related complications reported.
Implication: May influence prescriber choice and payer reviews pending full data.

Why it matters

Structural heart innovation is moving beyond replacement, with ViMech and Valvosoft targeting difficult aortic valve scenarios.
Workflow tools are becoming central to acute care, but STEMIcathAID still relies on clinician review rather than automated ECG interpretation.
Sex-stratified valve data reinforce individualized TAVR and SAVR decision-making.
FDA activity spans both AI clearance and device safety alerts, highlighting the dual focus on innovation and risk control.
Early feasibility studies in CMD and EP lead extraction point to new procedural options for underserved or higher-risk patients.

🚀 Accelerate your success. Contact us now

📂 Explore our case studies. See examples of our work.

💡 Read our insights. Learn from our latest reports and analysis

🎬 Watch on YouTube. Subscribe and never miss a video.

🧰 See our full range of services. Discover how we can help you.

📚 View the full Cardiovascular archive on our research hub page

FAQ

What is ViMech and which valve problem does it address?

ViMech is a valve-in-valve mechanical prosthesis strategy for failed mechanical aortic valves. It fractures dysfunctional discs, captures fragments, and places a TAVI valve. [1]

Does Mount Sinai’s STEMIcathAID use AI to read ECGs?

No. The current version does not include automated ECG analysis. It relies on physician review and clinician-to-clinician communication. [2]

Did the TAVR vs SAVR meta-analysis recommend sex-based treatment mandates?

No. The authors said findings support shared decision-making that considers sex, surgical risk, anatomy, comorbidities, life expectancy, and preferences. [3]

What did FDA clear for GuideAI Health?

FDA cleared VascularAssist Occlusion Triage, AI-powered software that flags suspected vascular occlusion for prioritized review in lower-extremity imaging. [4]

What is A-Flux Reducer System being studied for?

VahatiCor’s A-Flux Reducer System is being evaluated in SERRA-I for symptomatic coronary microvascular dysfunction. [5]

What is the Impella introducer sheath issue?

FDA warned of possible leakage from certain 14 French and 23 French introducers, which may cause access-site bleeding and require intervention. [7]

Entities / Keywords

ViMech: valve-in-valve mechanical prosthesis, mechanical aortic valve failure, TAVI, Ignacio Amat-Santos
STEMIcathAID: Mount Sinai Health System, STEMI, cath lab activation, ECG sharing, PCI
TAVR vs SAVR: transcatheter aortic valve replacement, surgical aortic valve replacement, severe aortic stenosis, sex-specific outcomes
GuideAI Health: VascularAssist Occlusion Triage, VAOT, FDA 510(k), PAD, vascular occlusion, AI triage
VahatiCor: A-Flux Reducer System, SERRA-I, coronary microvascular dysfunction, CMD, Yale-New Haven Hospital
Cardiawave: Valvosoft, noninvasive ultrasound therapy, NIUT, severe symptomatic aortic stenosis, CE mark
Johnson & Johnson MedTech: Impella, introducer sheath, Oscor, FDA early alert, bleeding risk
EP lead extraction: vibration-based extraction, locking stylet, pacemaker leads, ICD leads, JACC: Clinical Electrophysiology